Non-adherence to therapy is widely recognized as an ever-present problem in healthcare generally and the pharma industry specifically, which forgoes some $250 billion annually in lost sales. The picture is changing, somewhat, from past years, as health systems now have […]
Read MoreAs the US healthcare system continues to shift its reimbursement model from volume-based (fee for service) to value-based (fee for outcome), the landscape for specialty care is becoming increasingly complex. At the same time, a growing number of innovative specialty […]
Read MoreSponsored content Click on the link below to learn how PRMA Consulting has created an enhanced digital solution to analyze your organization’s readiness for payer submissions. Healthcheck_late_article
Read MoreThe business of providing outsourced patient support and hub services is growing in lockstep with the growth of specialty pharmaceuticals, which are now approaching nearly half of pharma spending in the US. Specialty pharmaceuticals are not only growing in number, […]
Read MoreProducts rise and fall in the marketplace for many different reasons, including formulary access, physician prescribing behaviors and competition. However, a cornerstone to a new therapy’s commercial success is the sales rep. How a rep is motivated can significantly impact […]
Read MoreOutsourced patient support services—aka hub programs—are a specialized area of business, but one that is both growing dramatically, and getting more crowded with providers. The latest entry is Diligent Health Solutions, based in Trevose, PA. Although small at the outset, […]
Read MoreThe news is that in January, Sanofi Pasteur gained FDA approval for a new indication for its branded Tdap vaccine, Adacel. Adacel has been on the market since the mid-2000s, approved as a booster shot for adolescents and adults. Now, […]
Read MoreUnlike other providers of electronic prior-authorization (ePA) support, who tend to be focused around the specifications of payer programs, ZappRx offers its support on a disease-specific (and in some cases, manufacturer-specific) basis. Having already set up programs for a variety […]
Read MoreJanuary brings a surge to new patient assistance programs (PAPs) which are charitable functions (with substantial pharma industry funding) to provide copay and other assistance to needy patients. Among some of the more prominent charity efforts, the Good Days / […]
Read MoreNews flash! The US pharma industry spends a lot of money promoting its products! But where this money gets spent, and whether it exerts an inappropriate influence on how consumers make healthcare choices, is an ongoing, fraught debate. A new […]
Read More